Abstract
Improving AI/ML services for ophthalmology and medicine Eric Buckland, PhD of Translational Imaging Innovations, delves into how we can achieve better transparency, traceability, and reproducibility in AI/ML for ophthalmology and medicine. Biomarkers are indispensable to finding cures and developing new therapies for degenerative eye diseases. Biomarkers are objectively measurable characteristics or indicators of normal biological processes, disease processes, or responses to therapeutic interventions. Biomarkers are essential to decision-making throughout drug development and patient care management. Dr. Buckland seeks to explain how biomarkers and clinical endpoints can transform ophthalmology, AI and ML for healthcare applications, and how biomarker development relies on transparency, traceability & reproducibility. Overall, Translational Imaging Innovations has committed to “delivering the most convenient and productive solutions for ophthalmic biomarker discovery and clinical endpoint validation”. TII aims to enable translational researchers to develop better diagnostics and better therapies with more predictable benefits – faster, cheaper, and less frustrating.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
